▴ Efalizumab is a humanized monoclonal antibody that binds to CD11a, the α-subunit of lymphocyte function-associated antigen-1, and consequently inhibits T-cell activation.
▴ In randomized, double-blind, placebo-controlled trials, efalizumab 1.0 mg/kg, administered subcutaneously once weekly for 12 weeks, significantly reduced disease activity in patients with chronic, moderate-to-severe plaque psoriasis. Significantly more efalizumab recipients had a ≥75% decrease in the Psoriasis Area and Severity Index (PASI) score [22.4–38.9%] than placebo recipients (2.4–4.9%); an additional 12 weeks of treatment resulted in sustained or increased PASI responses.
▴ The efficacy of weekly subcutaneous efalizumab was maintained during 15 months of treatment.
▴ Efalizumab significantly improved health-related quality of life in patients with chronic plaque psoriasis, with significant improvements in all the Dermatology Life Quality Index domains.
▴ Efalizumab was generally well tolerated in patients with chronic, moderate-to-severe plaque psoriasis, with few serious adverse events or treatment withdrawals. The most common adverse events were headache, chills, myalgia, pain, and fever; these most often occurred within 2 days of administration of the drug, were most frequent after the first or second dose, and decreased in frequency over time.
Psoriasis Plaque Psoriasis Dermatology Life Quality Index Efalizumab Fluocinolone Acetonide
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.
Cather JC, Cattier JC, Menter A. Modulating T cell responses for the treatment of psoriasis: a focus on efalizumab. Expert Opin Biol Ther. 2003 Apr; 3 (2): 361–70PubMedCrossRefGoogle Scholar
Prinz JC. The role of T cells in psoriasis. J Fur Acad Dermatol Venereol. 2003; 17 (3): 257–70CrossRefGoogle Scholar
Schön MP, Zollner TM, Boehncke WH. The molecular basis of lymphocyte recruitment to the skin: clues for pathogenesis and selective therapies of inflammatory disorders. J Invest Dermatol. 2003; 121 (5): 951–62PubMedCrossRefGoogle Scholar
Bauer RJ, Dedrick RL, White ML, et al. Population pharmacokinetics and pharmacodynamics of the anti-CD11a antibody hu1124 in human subjects with psoriasis. J Pharmacokinet Biopharm. 1999 Aug; 27 (4): 397–420PubMedGoogle Scholar
Gottlieb AB, Krueger JG, Wittkowski K, et al. Psoriasis as a model for T-cell-mediated disease: immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD1la antibody. Arch Dermatol. 2002 May; 138 (5): 591–600PubMedCrossRefGoogle Scholar
Werther WA, Gonzalez TA, O’Connonr SJ, et al. Humanization of an antilymphocyte function-associated antigen (LFA)-1 monoclonal antibody and reengineering of the humanized antibody for binding rhesus LFA-1. J Immunol. 1996; 157 (11): 4986–95PubMedGoogle Scholar
Dedrick RL, Bauer R, Bohmann D, et al. Pharmacokinetics and pharmacodynamics of subcutaneously administered anti-CD11a (hu1124) in psoriasis subjects [abstract no. 505 plus poster]. 59th Annual Meeting American Academy of Dermatology; 2001 Mar 2–7; Washington (DC)Google Scholar
Gottlieb A, Krueger JG, Bright R, et al. Effects of administrations of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis. J Am Acad Dermatol. 2000 Mar; 42: 428–35PubMedCrossRefGoogle Scholar
Krueger J, Gottlieb A, Miller B, et al. Anti-CD11a treatment for psoriasis concurrently increases circulating T-cells and decreases plaque T-cells, consistent with inhibition of cutaneous T-cell trafficking [abstract no. HB9]. J Invest Dermatol. 2000 Aug; 115 (2): 333PubMedCrossRefGoogle Scholar
Leonardi CL, Papp KA, Gordon KB, et al. Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial. J Am Acad Dermatol. 2005; 52 (3): 425–33PubMedCrossRefGoogle Scholar
Gordon KB, Papp KA, Hamilton TK, et al. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA. 2003 Dec 17; 290 (23): 3073–80PubMedCrossRefGoogle Scholar
Lebwohl M, Tyring SK, Hamilton TK, et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med. 2003 Nov 20; 349 (21): 2004–13PubMedCrossRefGoogle Scholar
Gottlieb AB, Gordon KB, Lebwohl MG, et al. Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasis. J Drugs Dermatol. 2004 Nov; 3 (6): 614–24PubMedGoogle Scholar
Ashcroft DM, Wan Po AL, Williams HC, et al. Clinical measures of disease severity and outcome in psoriasis: a critical appraisal of their quality. Br J Dermatol. 1999; 141: 185–91PubMedCrossRefGoogle Scholar
Menter A, Gordon K, Carey W, et al. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. Arch Dermatol. 2005 Jan; 141 (1): 31–8PubMedCrossRefGoogle Scholar